| Nome |
# |
|
Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation : A systematic review and meta-Analysis of 4,200,000 patients, file dfa8b9a9-0700-748b-e053-3a05fe0a3a96
|
341
|
|
Routine surgical videothoracoscopy as the first step of the planned resection for lung cancer, file dfa8b98f-e313-748b-e053-3a05fe0a3a96
|
307
|
|
Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada, file dfa8b9a2-8f6b-748b-e053-3a05fe0a3a96
|
159
|
|
Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases, file dfa8b991-f251-748b-e053-3a05fe0a3a96
|
134
|
|
Randomised controlled trials and real-life studies : two answers for one question, file dfa8b9a3-000f-748b-e053-3a05fe0a3a96
|
134
|
|
IPF: New insight in diagnosis and prognosis, file dfa8b9a2-9409-748b-e053-3a05fe0a3a96
|
123
|
|
Rare pulmonary diseases and orphan drugs: Where do we stand and where are we going to?, file dfa8b994-6841-748b-e053-3a05fe0a3a96
|
120
|
|
Pulmonary hypertension in chronic interstitial lung diseases, file dfa8b9a2-b320-748b-e053-3a05fe0a3a96
|
117
|
|
Fibrosing interstitial lung diseases : knowns and unknowns, file dfa8b9a3-6328-748b-e053-3a05fe0a3a96
|
117
|
|
An integrated approach in the diagnosis of smoking-related interstitial lung diseases, file dfa8b9a2-9faa-748b-e053-3a05fe0a3a96
|
116
|
|
Reversible airflow obstruction in lymphangioleiomyomatosis, file dfa8b9a2-b315-748b-e053-3a05fe0a3a96
|
115
|
|
Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study – Rationale and study design, file dfa8b9a2-c094-748b-e053-3a05fe0a3a96
|
115
|
|
Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis, file dfa8b9a2-f84d-748b-e053-3a05fe0a3a96
|
115
|
|
Lung cryobiopsy for the diagnosis of interstitial lung diseases: A series contribution to a debated procedure, file dfa8b9a2-a586-748b-e053-3a05fe0a3a96
|
109
|
|
Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis, file dfa8b9a2-8b2b-748b-e053-3a05fe0a3a96
|
108
|
|
The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy, file dfa8b9a2-da88-748b-e053-3a05fe0a3a96
|
105
|
|
Pulmonary hypertension in chronic lung disease and hypoxia, file dfa8b9a3-08c8-748b-e053-3a05fe0a3a96
|
105
|
|
Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia, file dfa8b9a3-e9dd-748b-e053-3a05fe0a3a96
|
101
|
|
Novel evidence for a greater burden of ambient air pollution on cardiovascular disease, file dfa8b9a3-c568-748b-e053-3a05fe0a3a96
|
94
|
|
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study, file dfa8b9a2-d0a2-748b-e053-3a05fe0a3a96
|
90
|
|
Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells, file dfa8b9a2-a585-748b-e053-3a05fe0a3a96
|
84
|
|
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis, file dfa8b9a2-ac64-748b-e053-3a05fe0a3a96
|
84
|
|
Comorbidities in idiopathic pulmonary fibrosis : an underestimated issue, file dfa8b9a3-6335-748b-e053-3a05fe0a3a96
|
84
|
|
The diagnosis of cystic lung diseases: A role for bronchoalveolar lavage and transbronchial biospy?, file dfa8b9a1-0ae8-748b-e053-3a05fe0a3a96
|
83
|
|
Thoracic-abdominal MDCT: A one-stop-shop procedure for diagnosis of lymphangioleiomyomatosis, file dfa8b9a2-d17c-748b-e053-3a05fe0a3a96
|
83
|
|
Fibrotic interstitial lung diseases and air pollution : a systematic literature review, file dfa8b9a5-651f-748b-e053-3a05fe0a3a96
|
83
|
|
Exercise-induced cardiac costraint by the lungs, file dfa8b9a2-a72e-748b-e053-3a05fe0a3a96
|
82
|
|
The changing face of a rare disease: Lymphangioleiomyomatosis, file dfa8b9a2-a72f-748b-e053-3a05fe0a3a96
|
79
|
|
Cellular interactions in the pathogenesis of interstitial lung diseases, file dfa8b9a2-c09f-748b-e053-3a05fe0a3a96
|
79
|
|
Need for deprescribing in hospital elderly patients discharged with a limited life expectancy: The REPOSI study, file dfa8b9a3-9131-748b-e053-3a05fe0a3a96
|
79
|
|
Giant Secondary Overgrowth of Type-1 Pulmonary Cystic Airway Malformation Upon Development of Anaplastic Lymphoma Kinase–Rearranged Adenocarcinoma, file dfa8b9a5-4e7a-748b-e053-3a05fe0a3a96
|
79
|
|
Hot off the breath: Mortality as a primary end-point in IPF treatment trials: The best is the enemy of the good, file dfa8b9a2-d334-748b-e053-3a05fe0a3a96
|
78
|
|
Beyond idiopathic pulmonary fibrosis : the world of progressive-fibrosing interstitial lung disease, file dfa8b9a3-5de0-748b-e053-3a05fe0a3a96
|
77
|
|
Rare (pulmonary) disease day: "Feeding the breath, energy for life!", file dfa8b9a2-d795-748b-e053-3a05fe0a3a96
|
76
|
|
Future perspectives on rare pulmonary diseases and rare presentations of common disorders, file dfa8b9a2-f8fc-748b-e053-3a05fe0a3a96
|
76
|
|
RISE-IIP : some pitfalls and observations, file dfa8b9a3-86f7-748b-e053-3a05fe0a3a96
|
76
|
|
Classification of pulmonary neuroendocrine tumors: New insights, file dfa8b9a2-ceee-748b-e053-3a05fe0a3a96
|
75
|
|
Everolimus for the treatment of lymphangioleiomyomatosis: A phase II study, file dfa8b9a2-f3d7-748b-e053-3a05fe0a3a96
|
75
|
|
Making the case for causality : what role do lung microbiota play in idiopathic pulmonary fibrosis?, file dfa8b9a3-01d5-748b-e053-3a05fe0a3a96
|
75
|
|
Severe idiopathic pulmonary fibrosis: What can be done?, file dfa8b9a2-8f6c-748b-e053-3a05fe0a3a96
|
74
|
|
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis, file dfa8b9a2-baf4-748b-e053-3a05fe0a3a96
|
74
|
|
New insights in lymphangioleiomyomatosis and pulmonary langerhans cell histiocytosis, file dfa8b9a2-c099-748b-e053-3a05fe0a3a96
|
74
|
|
Epidemiology of idiopathic pulmonary fibrosis in northern Italy, file dfa8b9a2-c09a-748b-e053-3a05fe0a3a96
|
74
|
|
Epidemiological studies in idiopathic pulmonary fibrosis: Pitfalls in methodologies and data interpretation, file dfa8b9a2-dc51-748b-e053-3a05fe0a3a96
|
74
|
|
The International LAM Registry: A component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform, file dfa8b9a2-e9eb-748b-e053-3a05fe0a3a96
|
74
|
|
LAM: Lymphangioleiomyomatosis: The patient and healthcare professional perspective, file dfa8b9a2-9b3b-748b-e053-3a05fe0a3a96
|
73
|
|
Pulmonary hypertension and chronic lung disease : where are we headed?, file dfa8b9a3-5dd9-748b-e053-3a05fe0a3a96
|
73
|
|
Impact of the post-COVID-19 condition on health care after the first disease wave in Lombardy, file 21717d58-a932-4c63-8e89-7188d4f90029
|
72
|
|
Global effort against rare and orphan diseases, file dfa8b9a2-a9f7-748b-e053-3a05fe0a3a96
|
72
|
|
Update on diffuse parenchymal lung disease, file dfa8b9a2-8f8f-748b-e053-3a05fe0a3a96
|
71
|
|
Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis, file dfa8b9a4-cd94-748b-e053-3a05fe0a3a96
|
71
|
|
The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models, file dfa8b9a2-98d4-748b-e053-3a05fe0a3a96
|
69
|
|
Rare pulmonary diseases: A path to the future, file dfa8b9a2-a2f3-748b-e053-3a05fe0a3a96
|
68
|
|
A 69-year-old female with multiple, bilateral pulmonary nodules, file dfa8b9a2-d78f-748b-e053-3a05fe0a3a96
|
68
|
|
Why we should care about ultra-rare disease, file dfa8b9a2-d336-748b-e053-3a05fe0a3a96
|
67
|
|
Pulmonary hypertension in patients with chronic myeloproliferative disorders, file dfa8b9a2-d794-748b-e053-3a05fe0a3a96
|
67
|
|
Early consensus management for non-ICU acute respiratory failure SARS-CoV-2 emergency in Italy : from ward to trenches, file dfa8b9a3-5c4d-748b-e053-3a05fe0a3a96
|
67
|
|
Recent advances in managing idiopathic pulmonary fibrosis., file dfa8b9a3-bb5f-748b-e053-3a05fe0a3a96
|
67
|
|
Idiopathic Pulmonary Fibrosis for Cardiologists : Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management, file dfa8b9a3-08c0-748b-e053-3a05fe0a3a96
|
66
|
|
Rare pulmonary disease and orphan drugs : a path to the future, file dfa8b9a3-3992-748b-e053-3a05fe0a3a96
|
66
|
|
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone, file dfa8b9a2-c090-748b-e053-3a05fe0a3a96
|
65
|
|
Toward better management of rare and orphan pulmonary diseases, file dfa8b9a2-f242-748b-e053-3a05fe0a3a96
|
64
|
|
Understanding the priorities for women diagnosed with lymphangioleiomyomatosis: A patient perspective, file dfa8b9a2-be62-748b-e053-3a05fe0a3a96
|
63
|
|
Idiopathic pulmonary fibrosis and sleep disorders: No longer strangers in the night, file dfa8b9a2-8f73-748b-e053-3a05fe0a3a96
|
61
|
|
Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial, file dfa8b9a2-be63-748b-e053-3a05fe0a3a96
|
61
|
|
Thoracic involvement in generalised lymphatic anomaly (or lymphangiomatosis), file dfa8b9a2-d796-748b-e053-3a05fe0a3a96
|
61
|
|
The revolution of pulmonary arterial hypertension, file dfa8b9a2-da9d-748b-e053-3a05fe0a3a96
|
61
|
|
Lymphangioleiomyomatosis: What do we know and what are we looking for?, file dfa8b9a2-de2a-748b-e053-3a05fe0a3a96
|
61
|
|
Rare pulmonary diseases: A common fight, file dfa8b9a2-9851-748b-e053-3a05fe0a3a96
|
60
|
|
Pulmonary hypertension in lymphangioleiomyomatosis: Characteristics in 20 patients, file dfa8b9a2-a854-748b-e053-3a05fe0a3a96
|
60
|
|
Estimates of the initial impact of the COVID-19 epidemic on overall mortality: evidence from Italy, file dfa8b9a4-c9da-748b-e053-3a05fe0a3a96
|
60
|
|
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal, file dfa8b9a6-0a24-748b-e053-3a05fe0a3a96
|
59
|
|
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist, file dfa8b9a2-97eb-748b-e053-3a05fe0a3a96
|
57
|
|
The goal is to go further and do better: But how?, file dfa8b9a2-de19-748b-e053-3a05fe0a3a96
|
57
|
|
The changing face of the European respiratory review, file dfa8b9a3-01cd-748b-e053-3a05fe0a3a96
|
57
|
|
Correction: Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial, file dfa8b9a2-c01f-748b-e053-3a05fe0a3a96
|
55
|
|
Ultra-rare disease : an European perspective, file dfa8b9a5-4f3e-748b-e053-3a05fe0a3a96
|
55
|
|
Pulmonary hypertension: A paradigm for rare pulmonary diseases, file dfa8b9a2-9850-748b-e053-3a05fe0a3a96
|
54
|
|
Adding new perspectives to the European respiratory review, file dfa8b9a2-ec42-748b-e053-3a05fe0a3a96
|
54
|
|
Who's Afraid of the Big Bad Wolf? Safety of Beta-Blockers in COPD, file dfa8b9a3-a8d6-748b-e053-3a05fe0a3a96
|
53
|
|
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study, file dfa8b9aa-2498-748b-e053-3a05fe0a3a96
|
53
|
|
Out with the old, in with the new for the European respiratory review, file dfa8b9a2-ade7-748b-e053-3a05fe0a3a96
|
51
|
|
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19, file dfa8b9a9-ddbe-748b-e053-3a05fe0a3a96
|
50
|
|
Idiopathic pulmonary fibrosis: From clinical trials to real-life experiences, file dfa8b9a2-9386-748b-e053-3a05fe0a3a96
|
48
|
|
Clinical course of IPF in Italian patients during 12 months of observation : results from the FIBRONET observational study, file dfa8b9a8-6f8e-748b-e053-3a05fe0a3a96
|
48
|
|
Correction to: Treat all COVID 19‑positive patients, but do not forget those negative with chronic diseases, file dfa8b9a5-45c5-748b-e053-3a05fe0a3a96
|
47
|
|
Morphologic and molecular classification of lung neuroendocrine neoplasms, file dfa8b9a8-455f-748b-e053-3a05fe0a3a96
|
45
|
|
Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal, file dfa8b9a1-c473-748b-e053-3a05fe0a3a96
|
39
|
|
MTOR inhibitors and risk of ovarian cysts : A systematic review and meta-analysis, file dfa8b9a9-2a33-748b-e053-3a05fe0a3a96
|
27
|
|
The usefulness of D-dimer as a predictive marker for mortality in patients with COVID-19 hospitalized during the first wave in Italy, file db128e03-eac2-428f-848a-ad2a43f6c88f
|
20
|
|
Sarcopenia in idiopathic pulmonary fibrosis: a prospective study exploring prevalence, associated factors and diagnostic approach, file 53e70e41-1a58-4ff9-808f-9f880a530c8a
|
16
|
|
Recent advances in the management of pulmonary hypertension with interstitial lung disease, file 66c0dc79-71c1-4b34-8bbe-61c149e3de42
|
14
|
|
The 6-min walk test as a primary end-point in interstitial lung disease, file a17a029c-ffd9-4801-862f-9acdf6c58d58
|
14
|
|
Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis, file dfa8b99f-7bbd-748b-e053-3a05fe0a3a96
|
14
|
|
Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period, file 84d89890-7159-4854-a52a-c5c101e0a7bf
|
13
|
|
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy, file d62fcb8c-c16a-4513-be3d-a2fb4770728d
|
13
|
|
The curious incident of long COVID symptoms, from an imaginary condition to a recognised syndrome: a "small victory", file 98dd6801-0607-47e9-b614-246a1f8230ec
|
10
|
|
One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study, file 858fd169-7fa4-42ca-a2c2-aaca3d731d77
|
8
|
|
Incremental prognostic value of global left atrial peak strain in women with new-onset gestational hypertension, file dfa8b9a3-0394-748b-e053-3a05fe0a3a96
|
6
|
|
Symptomatic post COVID patients have impaired alveolar capillary membrane function and high VE/VCO2, file 0e478e22-fff8-4cc9-8fe7-2f07225632e9
|
5
|
| Totale |
7.432 |